Drugmakers and Top Biotech Stocks Regeneron and Sanofi have announced positive outcome from a one year study of the Dupixent product which is used in the treatment of moderate-to-severe atopic dermatitis (AD) or eczema.
Acording to a statement from the companies, Dupixent used together with corticosteroids registered improved clearance of skin lesions as well as the overall severity of the disease. Principal investigator of the study, Andrew Blauvelt said the study will offer lasting and reliable data for Dupixent which is very important owing to the fact that dermatitis is a chronic disease.
An application for biologics licence for Dupixent was reviewed and accepted by Food and Drug Administration (FDA). The application was categorized for priority review.
In other segment Sanofi which is also Biotechnology Stocks signed a $524.6 million deal with MedImmune for RSV drug. In the deal the two companies will jointly develop, commercialize and market an RSV drug candidate.
The drug candidate referred to as MEDI8897 was developed by MedImmune a branch of AstraZeneca specializing in research and development. It is used to reduce respiratory diseases that are caused by RSV or syncytial in infants.
The candidate that was assigned fast track development status by Food and Drug Administration in 2015 is currently at stage 2b clinical examination and is being administered to children who cannot be treated using Synagis, a prophylaxis type of MedImmune. Synagis which has been the preferred treatment for a long time for high risk babies once recorded $1 billion sales a year but later fell sharply in 2015 after losing patent protection.
RSV is a major cause of illness among infants and equally seniors. According to estimates by Centers for Disease Control, around 177,000 beyond the age of 65 in the United States are hospitalized out of which 14,000 succumb to RSV as well as its complications.
In the deal, Sanofi will make a down payment of $127.1 million toward MEDI8897 development. An additional $524.6 million will be paid upon reaching certain sales and development milestones. Both companies will equally share profits and costs.